Empliciti (elotuzumab) is a monoclonal antibody that’s used to treat a certain type of blood cancer called multiple myeloma. It’s an intravenous infusion that’s given at an infusion center or provider’s office. This medication can cause side effects such as infusion reactions, diarrhea, and low blood cell counts. You typically take Empliciti (elotuzumab) as part of a cancer treatment plan with two medications that you take by mouth (an immunomodulatory drug and dexamethasone).
Multiple myeloma in people who’ve already taken 1 to 3 therapies; given with lenalidomide (Revlimid) and dexamethasone
Multiple myeloma in people who’ve already taken at least 2 therapies; given with Pomalyst (pomalidomide) and dexamethasone
Multiple myeloma is a type of cancer that develops in certain kinds of blood cells called plasma cells (a type of immune cell). The multiple myeloma cancer cells have a protein on their surface called SLAMF7. This protein is also found on the outside of certain other cells in your immune system.
Empliciti (elotuzumab) is a monoclonal antibody that targets the SLAMF7 protein. The medication attaches to SLAMF7 on multiple myeloma cells and the other immune system cells. This tells the immune system to come attack the cancer cell. As a result, the multiple myeloma cancer cells can’t grow and spread as well.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Recommended treatment option for certain people with multiple myeloma who’ve previously had therapy
Only need infusions once or twice per month after the first two treatment cycles
Works in a more specific, targeted way than traditional chemotherapy
Given intravenously (through a vein), so requires a needle for administration
Might cause serious infusion-related reactions
Might cause liver problems, so regular lab test monitoring is required
Empliciti (elotuzumab) is often given together with other medications to treat multiple myeloma, and it can sometimes be difficult to keep track of the treatment schedule. Talk to your provider about using a treatment calendar so all your appointments and treatment doses are written down. You can also consider using an app on your phone to help you remember.
If you have diarrhea while you’re taking Empliciti (elotuzumab), make sure you drink plenty of fluids. Avoid sugary sports drinks, though, because they can make diarrhea worse. Your provider might recommend over-the-counter diarrhea medications, like loperamide (Imodium A-D), to help.
Check your temperature at least once a day. Call your provider as soon as possible if you have a fever (a temperature that’s 100.4 degrees Fahrenheit or higher). It’s important for your provider to know if you get sick, and sometimes a fever might be the only sign that you’re sick.
If you have diabetes and you typically check your blood sugar at home, talk to your provider about what blood sugar levels are unsafe for you. Also ask when you should contact them with your results. You might have higher blood sugar during treatment, especially on days when you take dexamethasone, one of the medications that’s given together with Empliciti (elotuzumab).
You shouldn’t breastfeed while you’re getting treated with Empliciti (elotuzumab). We don’t know whether the medication passes into human breast milk. But it has a potential risk of harming a baby if it does based on what we know about the way Empliciti (elotuzumab) works. The other medications that are usually given with Empliciti (elotuzumab) can also cause harm to breastfed babies.
Empliciti (elotuzumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Some people taking Empliciti (elotuzumab) developed an infusion reaction during their treatment. Symptoms of an infusion reaction include fever, chills, chest pain or tightness, and changes in blood pressure. Most of the time, these reactions happen when you get your first dose of Empliciti (elotuzumab).
To prevent an infusion reaction, you’ll typically receive several medications before your Empliciti (elotuzumab) treatment; these “premedications” can include diphenhydramine (Benadryl) and acetaminophen (Tylenol). But reactions can still occur even with these medications. Let your nurse know right away if you experience symptoms of an infusion reaction during your treatment.
People who take Empliciti (elotuzumab) commonly develop infections, such as a cold, pneumonia, and shingles. You’re at risk for infections because your immune system might not work as well when you have multiple myeloma. Additionally, the treatment you take for multiple myeloma, such as Empliciti (elotuzumab) and immunomodulatory drugs, can lower your immune system even more. As a result, your body can’t fight infections as well.
Your provider might recommend you take certain medications, such as antivirals or antibiotics, to help prevent infections. It’s important that you check your body temperature regularly and seek medical attention right away if it’s ever 100.4 degrees Fahrenheit or higher. This means that you have a fever, and it might mean you have an infection that needs further treatment.
Though uncommon, some people taking Empliciti (elotuzumab) developed a new cancer. Skin cancers were most common in studies. Your provider will examine you for any new cancers (especially skin cancers) while you’re taking Empliciti (elotuzumab).
Rarely, people taking Empliciti (elotuzumab) had higher levels of liver enzymes on their lab tests. High liver enzymes can result from liver irritation. Your provider will regularly check your liver function with lab tests during treatment. If you have changes in your lab results, you might have to pause Empliciti (elotuzumab) while your provider looks into it.
Empliciti (elotuzumab) can interfere with certain lab tests that are used to track how well your multiple myeloma is responding to treatment. This interference can lead to abnormal results on these lab tests. Your provider should be aware of this lab interference. They’ll discuss with you about your response to Empliciti (elotuzumab) treatment.
The dose depends on your body weight and which treatment combination you’re taking. Empliciti (elotuzumab) is given as an infusion through the vein during each 28-day treatment cycle.
For people taking Empliciti (elotuzumab) with lenalidomide (Revlimid) and dexamethasone
Cycles 1 and 2: The usual dose of Empliciti (elotuzumab) is 10 mg/kg of weight once per week.
Cycle 3 and onward: The usual dose of Empliciti (elotuzumab) is 10 mg/kg every other week.
For people taking Empliciti (elotuzumab) with Pomalyst (pomalidomide) and dexamethasone
Cycles 1 and 2: The usual dose of Empliciti (elotuzumab) is 10 mg/kg of weight once per week.
Cycle 3 and onward: The usual dose of Empliciti (elotuzumab) is 20 mg/kg once every 4 weeks (i.e., on day 1 of each cycle).
Multiple myeloma in people who’ve already taken 1 to 3 therapies; given with lenalidomide (Revlimid) and dexamethasone
Multiple myeloma in people who’ve already taken at least 2 therapies; given with Pomalyst (pomalidomide) and dexamethasone
Multiple myeloma in people whose cancer came back after receiving anticancer treatments
Multiple myeloma that’s been previously treated with at least one therapy
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
American Cancer Society. (2018). Tests to find multiple myeloma.
American Cancer Society. (2018). What is multiple myeloma?
American Cancer Society. (2019). Immunomodulators and their side effects.
American Cancer Society. (2020). Fever.
American Cancer Society. (2020). Low platelet count (bleeding).
American Cancer Society. (2020). What are infusion or immune reactions?
American Cancer Society. (2021). How targeted therapies are used to treat cancer.
American Cancer Society. (2023). Low white blood cell counts (neutropenia).
Cesarman-Maus, G., et al. (2012). Thrombosis in multiple myeloma (MM). Hematology.
Conroy, M., et al. (2022). Immune-related adverse events and the balancing act of immunotherapy. Nature Communications.
Díaz-Tejedor, A., et al. (2021). Immune system alterations in multiple myeloma: Molecular mechanisms and therapeutic strategies to reverse immunosuppression. Cancers.
Dimopoulos, M. A., et al. (2020). Elotuzumab, lenalidomide, and dexamethasone in RRMM: Final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer Journal.
E.R. Squibb & Sons, L.L.C. (2022). Emplicity- elotuzumab injection, powder, lyophilized, for solution [package insert]. DailyMed.
Holstein, S. A., et al. (2017). Immunomodulatory drugs in multiple myeloma: Mechanisms of action and clinical experience. Drugs.
InformedHealth.org. (2023). How does the immune system work? Institute for Quality and Efficiency in Health Care.
Key, N. S., et al. (2023). Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. Journal of Clinical Oncology.
Kikuchi, J., et al. (2020). Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia.
Magen, H., et al. (2016). Elotuzumab: The first approved monoclonal antibody for multiple myeloma treatment. Therapeutic Advances in Hematology.
Minařík, J., et al. (2022). Immunomodulatory agents for multiple myeloma. Cancers.
National Cancer Institute. (n.d.). Plasma cell.
National Cancer Institute. (2022). Targeted therapy to treat cancer.
National Comprehensive Cancer Network. (2021). Anemia and neutropenia: Low red and white blood cell counts.
National Comprehensive Cancer Network. (2023). Multiple myeloma.
Wang, Y., et al. (2016). Elotuzumab for the treatment of multiple myeloma. Journal of Hematology and Oncology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.